CTRI/2012/11/003124已完成未知
A randomized controlled parallel group study on 2-octyl cyanoacrylate versus non-absorbable simple interrupted sutures in the closure of skin incisions at laparoscopic port sites
Seth GS Medical College and KEM Hospital0 个研究点目标入组 20 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •undergoing elective laparoscopic surgery
排除标准
- •Refusal to consent
- •Refusal to follow up
研究者
相似试验
已完成
不适用
A randomised controlled parallel group study of a culturally focused cardiac rehabilitation programme - an efficacy trial (CADISAP)ISRCTN51525117Department of Health150
招募中
不适用
A randomized parallel-group controlled study for personalized postoperative pain management based on prediction of fentanyl requirements by genetic polymorphisms in patients undergoing orthognathic surgeryPainJPRN-UMIN000006805Tokyo Metropolitan Institute of Medical Science300
招募中
4 期
A Randomized Parallel Group Controlled Study between 3.75 mg of Leuprorelin and 1.8 mg of Goserelin Depot in the Sequential Therapy (GnRH Agonist + Dienogest) for Treatment of Endometriosisendometriosis, chocolate cyst or adenomyosis uteriJPRN-UMIN000010332Tokyo Women's Medical University Department of Obstetrics and Gynecology120
进行中（未招募）
1 期
A randomized, double-blind, parallel group study of the safety and reduction of signs and symptoms during treatment with MRA versus placebo, in combination with methotrexate, in patients with moderate to severe active rheumatoid arthritis.Rheumatoid ArthritisEUCTR2004-003741-40-SKF. Hoffmann La-Roche AG630
进行中（未招募）
不适用
A global study to investigate the safety and effect on clinical outcome of tocilizumab given subcutaneously versus tocilizumab given intravenously, in combination with traditional disease-modifying anti-rheumatic drugs (DMARDs), in patients with moderate to severe active rheumatoid arthritis.MedDRA version: 14.1Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersRheumatoid arthritisEUCTR2010-018375-22-BGF. Hoffmann-La Roche Ltd1,200